Consensus Ashland Inc.

Stocks

ASH

US0441861046

Diversified Chemicals

Market Closed - NYSE 21:00:02 05/10/2026 BST			5-day change	1st Jan Change
68.78 ^USD	-1.06%		+1.04%	+17.23%

09-17	Ashland Inc. - Analyst/Investor Day
08-24	Ashland Inc. Launches Permexa Sodium Caprate to Support Scalable Development and Commercialization of Oral Peptide, Biologic and Low-Permeability Drug Products	CI

Evolution of the Average Target: Ashland Inc.

Evolution of the Target Price: Ashland Inc.

Changes in Analyst Recommendations: Ashland Inc.

64242a778fb2025ef.0LvW3wgOIIFFQFxeLzKvD6O4a92HVrf9QhGFbYNcEQo.gtPh70s2EuAkIhILQETZPNHhG7n2EN_Lc07NCsw_I2Gi6JGqRW94xxIiNw~7fac0aae743452cda0b93f01840a7542

Analysts' recommendations: Ashland Inc.

10-05	UBS Adjusts Ashland Price Target to $80 From $83, Maintains Buy Rating	MT
08-06	Ashland's Fundamentals Appear to Improve With a Fiscal Q3 Beat, Morgan Stanley Says	MT
08-06	Morgan Stanley Adjusts Price Target on Ashland to $78 From $58, Maintains Equalweight Rating	MT
07-31	Deutsche Bank Adjusts Ashland Price Target to $85 From $74, Maintains Buy Rating	MT
07-30	UBS Adjusts Price Target on Ashland to $83 From $75, Maintains Buy Rating	MT
06-15	Deutsche Bank Adjusts Ashland Price Target to $74 From $60, Maintains Buy Rating	MT
06-10	UBS Lifts Ashland Price Target to $72 From $66, Maintains Buy Rating	MT
05-06	Seaport Upgrades Ashland to Buy From Neutral, Sets $75 Price Target	MT
05-04	Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says	MT
05-04	Morgan Stanley Lowers Price Target on Ashland to $58 From $63, Keeps Equalweight Rating	MT
04-06	Mizuho Cuts Price Target on Ashland to $65 From $70, Keeps Outperform Rating	MT
02-04	UBS Adjusts Price Target on Ashland to $73 From $70, Maintains Buy Rating	MT
02-04	Deutsche Bank Adjusts Ashland Price Target to $70 From $58, Maintains Buy Rating	MT
01-12	UBS Adjusts Price Target on Ashland to $70 From $64, Maintains Buy Rating	MT
12-18	Mizuho Securities Adjusts Ashland Price Target to $70 From $60, Maintains Outperform Rating	MT
12-15	Ashland Shares Rise After BMO Capital Upgrade	MT
12-15	BMO Capital Upgrades Ashland to Outperform From Market Perform, Adjusts PT to $71 From $61	MT
11-12	Deutsche Bank Raises Price Target on Ashland to $58 From $55, Keeps Buy Rating	MT
03/10/25	Mizuho Lowers Price Target on Ashland to $54 From $58, Keeps Outperform Rating	MT
30/09/25	Deutsche Bank Cuts Price Target on Ashland to $55 From $62, Keeps Buy Rating	MT
08/09/25	Morgan Stanley Initiates Coverage on Ashland With Equal Weight Rating, $60 Price Target	MT
07/08/25	UBS Adjusts Price Target on Ashland to $64 From $73, Maintains Buy Rating	MT
09/07/25	UBS Trims Price Target on Ashland to $73 From $74, Maintains Buy Rating	MT
02/05/25	Wells Fargo Downgrades Ashland to Equalweight From Overweight, Adjusts Price Target to $50 From $58	MT
01/05/25	UBS Adjusts Price Target on Ashland to $74 From $85, Maintains Buy Rating	MT

More recommendations

Diversified Chemicals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ASHLAND INC.					+16.18%
	SHIN-ETSU CHEMICAL CO., LTD.					+24.85%
	BASF SE					+4.45%
	PIDILITE INDUSTRIES LIMITED					+19.43%
	ASAHI KASEI CORPORATION					+18.84%
	MITSUBISHI CHEMICAL GROUP CORPORATION					+10.86%
	BRENNTAG SE					-2.71%
	SYENSQO SA/NV					+3.97%
	SASOL LIMITED					-9.63%
	SRF LIMITED					+18.85%
	Average					+10.51%
	Weighted average by Cap.					+14.18%